Gynecologic Oncology Articles | Page 2

AXL Kinase Becomes a Therapeutic Target in Its Own Right
Despite being implicated across the spectrum of cancer hallmarks, aberrant AXL signaling is just starting to emerge as a distinct anticancer target, with a growing focus on specific inhibitors as well as alternative novel drug designs.
The China National Medical Products Administration has accepted a supplemental New Drug Application for niraparib for use as a frontline maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
Expert Encourages Use of Sentinel Lymph Node Staging in Endometrial Cancer
Carrie L. Langstraat, MD, discusses the role of sentinel lymph node biopsy in endometrial cancer.
NUC-1031 Shows Early Promise in Heavily Pretreated Platinum-Resistant Ovarian Cancer
The first-in-class nucleotide analogue NUC-1031 has demonstrated early clinical activity in heavily pretreated patients with platinum-resistant ovarian cancer.
FDA Grants Balstilimab/Zalifrelimab Dual Immunotherapy Fast Track Designation in Cervical Cancer
The FDA has granted a Fast Track designation to the combination of the PD-1 inhibitor balstilimab and the CTLA-inhibitor zalifrelimab for the treatment of patients with relapsed or refractory metastatic cervical cancer.
Cediranib/Olaparib Combo Falls Short in Phase III Relapsed Ovarian Cancer Trial
Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. 
FDA Approves Cytology Test to Enhance Cervical Cancer Prevention
The FDA has approved the CINtec PLUS Cytology test as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus using the cobas 4800 HPV Test. 
Routine Cervical Cancer Screening Reduces Risk of Stage I/II+ Disease, But More Awareness Needed
Routine cervical screening, conducted every 3 years, was found to reduce the incidence of stage I and stage II+ cervical cancers by 48% and 83%, respectively.
FDA Takes Action on Safety Measures With Laparoscopic Power Morcellators for Gynecologic Surgery
In an effort to make the use of laparoscopic power morcellators a safer and more effective choice in gynecologic surgeries, the FDA has released a statement that it will be putting a handful of strategies and recommendations in place.
Frontline Maintenance Niraparib Takes Step Toward EU Approval in Ovarian Cancer
The European Medicines Agency has validated a Type II Variation for niraparib as a first-line maintenance treatment for patients with advanced ovarian cancer who have responded to platinum-based chemotherapy, regardless of biomarker status.
Publication Bottom Border
Border Publication